<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">Subsequently, two prospective studies with RSV immunoprophylaxis have been performed to address the potential causality between RSV infection and subsequent asthma. In these recent randomized controlled trials, pre-term infants who received palivizumab demonstrated a decreased number of recurrent wheezing episodes, but the incidence of physician-diagnosed asthma at age 6 remained intact [
 <xref ref-type="bibr" rid="CR74">74</xref>, 
 <xref ref-type="bibr" rid="CR75">75</xref>]. These effects, however, were less noticeable in infants with atopic family history, indicating that RSV infection is not causal to asthma or atopy development.
</p>
